Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

In Honor of World MS Day Opexa Therapeutics to Ring The NASDAQ Stock Market Closing Bell on May 28



  In Honor of World MS Day Opexa Therapeutics to Ring The NASDAQ Stock Market
  Closing Bell on May 28

Business Wire

THE WOODLANDS, Texas -- May 28, 2013

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing
Tcelna^TM, a patient specific T-cell immunotherapy for the treatment of
multiple sclerosis (MS), today announced it will visit the NASDAQ MarketSite
to ring the Closing Bell on Tuesday, May 28, 2013, at 4:00 pm EDT.

In honor of World MS Day, Opexa's President and Chief Executive Officer, Neil
K. Warma, joined by other members of the Opexa team, will ring the Closing
Bell.

“We are very pleased to be invited to ring the Closing Bell on the eve of
World MS Day,” commented Mr. Warma. “World MS Day will be celebrated this year
on May 29th and was developed in 2009 by the Multiple Sclerosis International
Federation (MSIF) to raise global awareness of MS and how it affects more than
2 million people worldwide. At Opexa, we are committed to the MS community and
to the development of Tcelna^TM, a novel immunotherapy for the treatment of
Secondary Progressive MS. In addition, we are pleased to be associated with
the NASDAQ Stock Market as it is through them that we gain access to those
investors who support research and development in novel therapies for medical
disorders with high unmet needs, such as MS.”

A live webcast of the NASDAQ Closing Bell will be available at:
http://www.nasdaq.com/about/marketsitetowervideo.asx.

About Opexa

Opexa’s mission is to lead the field of precision immunotherapy by aligning
the interests of patients, employees and share holders. The Company’s leading
therapy candidate, Tcelna™, is a personalized T-cell immunotherapy that is in
a Phase IIb clinical development program (the Abili-T trial) for the treatment
of Secondary Progressive Multiple Sclerosis. Tcelna is derived from T-cells
isolated from the patient’s peripheral blood, expanded ex vivo, and
reintroduced into the patients via subcutaneous injections. This process
triggers a potent immune response against specific subsets of autoreactive
T-cells known to attack myelin.

About Multiple Sclerosis (MS)

Multiple Sclerosis is a chronic, inflammatory condition of the central nervous
system and is the most common, non-traumatic, disabling neurological disease
in young adults. It is estimated that approximately two million people have MS
worldwide. While symptoms can vary, the most common symptoms of MS include
blurred vision, numbness or tingling in the limbs and problems with strength
and coordination. The relapsing forms of MS are the most common. The Secondary
Progressive form of MS represents about a third of the MS patient population.

About Tcelna

Tcelna is a potential personalized therapy that is under development to be
specifically tailored to each patient's disease profile. Tcelna is
manufactured using ImmPath™, Opexa's proprietary method for the production of
a patient-specific T-cell immunotherapy, which encompasses the collection of
blood from the MS patient, isolation of peripheral blood mononuclear cells,
generation of an autologous pool of myelin-reactive T-cells (MRTCs) raised
against selected peptides from myelin basic protein (MBP), myelin
oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the
return of these expanded, irradiated T-cells back to the patient. These
attenuated T-cells are reintroduced into the patient via subcutaneous
injection to trigger a therapeutic immune system response.

Opexa is currently conducting a Phase IIb study of Tcelna. Named “Abili-T,”
the trial is a randomized, double-blind, placebo-controlled clinical study in
patients who demonstrate evidence of disease progression with or without
associated relapses. The trial is expected to enroll 180 patients at
approximately 30 leading clinical sites in the U.S. and Canada with each
patient receiving two annual courses of Tcelna treatment consisting of five
subcutaneous injections per year. The trial’s primary efficacy outcome is the
percentage of brain volume change (atrophy) at 24 months. Study investigators
will also measure several important secondary outcomes commonly associated
with MS, including disease progression as measured by the Expanded Disability
Status Scale (EDSS), annualized relapse rate and changes in disability as
measured by EDSS and the MS Functional Composite.

For more information visit the Opexa Therapeutics website at
www.opexatherapeutics.com

Contact:

Opexa Therapeutics, Inc.
Karthik Radhakrishnan, 281-775-0600
Chief Financial Officer
kradhakrishnan@opexatherapeutics.com
or
Investor Relations
The Trout Group
Adam Cutler, 646-378-2936
opexa@troutgroup.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement